Bharat Biotech Latest News
- All
- News
-
Bharat Biotech Begins Clinical Trials Of TB Vaccine On Adults In India
Bharat Biotech International Ltd on Sunday said it started clinical trials of the Tuberculosis vaccine Mtbvac on adults in India.
-
WHO Suspends UN Supply Of Covaxin; No Impact On Efficacy, Says Bharat Biotech
The World Health Organisation said on Saturday it has suspended supply through United Nations agencies of COVID-19 vaccine Covaxin, produced by India's Bharat Biotech, to allow the manufacturer to upgrade facilities.
-
Chief Justice Stresses On Respecting Mother, Mother Tongue And Motherland
Chief Justice of India NV Ramana on Thursday presented the Dr Ramineni Foundation's awards to vaccine maker Bharat Biotech's MD Krishna Ella and several others for their meritorious services.
-
After Call To Cut Covishield Dose Gap, Government's Clarification
There is no plan to reduce the 84-day dose gap for Covishield, top government expert NK Arora said today as reports said the interval between two shots will be reviewed for the third time this year following a recommendation by health experts.
-
Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.
-
Latest News Updates: India Records Over 17,000 COVID-19 Cases In 24 Hours
Single day rise of 17,407 new COVID-19 cases and 89 fatalities has pushed India's tally of cases to 1,11,56,923 and death count to 1,57,435, according to the Union Health Ministry data this morning
-
Latest News Highlights: Covaxin Shows Interim Clinical Efficacy Of 81% In Phase 3 Results, Says Bharat Biotech
Phase 3 results for Bharat Biotech's coronavirus vaccine - Covaxin - were released Wednesday afternoon, with the drug demonstrating "81 per cent interim efficacy in preventing COVID-19 in those without prior infection after the second dose", according to a statement by the company.
-
Bharat Biotech Gets Centre's Letter For 45 Lakh Doses Of Covaxin: Report
Bharat Biotech has secured a fresh Letter of Comfort from the Centre for another 45 lakh doses of its COVID-19 vaccine, Covaxin, sources said.
-
"Every Indian Proud That Vaccines Given Approval Made In India": PM Modi
India COVID-19 Vaccine: It would make every Indian proud that the two COVID-19 vaccines given go-ahead by the country's drug controller are "made in India", PM Modi today said within minutes of the approval being made public.
-
India A Step Closer To Covid Vaccine, Drug Regulator Approval Awaited: 10 Facts
India has moved a step closer to getting a coronavirus vaccine as two candidates - Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield - have been recommended by a government-appointed panel to the Drugs Controller General of India (DCGI) for emergency use in the last two days. The country has been preparing for t...
-
Coronavirus Highlights: Oxford COVID-19 Vaccine Covishield Approved For Use In India
India's drugs regulator on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
-
Coronavirus LIVE Updates: Bharat Biotech Seeks Emergency Use Approval For Covaxin
Coronavirus Updates: India recorded 32,981 new COVID-19 cases in the last 24 hours, taking the total number of active coronavirus cases in the country to 3,96,729, said the Union Ministry of Health and Family Welfare on Monday.
-
Vaccine Maker Clarifies As Haryana Minister, A Volunteer, Tests Covid+
Covaxin, India's first indigienous vaccine for the highly infectious coronavirus, has been designed to be effective if a person takes two doses, Hyderabad-based pharmaceutical firm Bharat Biotech clarified in a statement on Saturday, stressing that the "efficacy can be determined 14 days after the second dose".
-
Bharat Biotech Begins Clinical Trials Of TB Vaccine On Adults In India
Bharat Biotech International Ltd on Sunday said it started clinical trials of the Tuberculosis vaccine Mtbvac on adults in India.
-
WHO Suspends UN Supply Of Covaxin; No Impact On Efficacy, Says Bharat Biotech
The World Health Organisation said on Saturday it has suspended supply through United Nations agencies of COVID-19 vaccine Covaxin, produced by India's Bharat Biotech, to allow the manufacturer to upgrade facilities.
-
Chief Justice Stresses On Respecting Mother, Mother Tongue And Motherland
Chief Justice of India NV Ramana on Thursday presented the Dr Ramineni Foundation's awards to vaccine maker Bharat Biotech's MD Krishna Ella and several others for their meritorious services.
-
After Call To Cut Covishield Dose Gap, Government's Clarification
There is no plan to reduce the 84-day dose gap for Covishield, top government expert NK Arora said today as reports said the interval between two shots will be reviewed for the third time this year following a recommendation by health experts.
-
Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.
-
Latest News Updates: India Records Over 17,000 COVID-19 Cases In 24 Hours
Single day rise of 17,407 new COVID-19 cases and 89 fatalities has pushed India's tally of cases to 1,11,56,923 and death count to 1,57,435, according to the Union Health Ministry data this morning
-
Latest News Highlights: Covaxin Shows Interim Clinical Efficacy Of 81% In Phase 3 Results, Says Bharat Biotech
Phase 3 results for Bharat Biotech's coronavirus vaccine - Covaxin - were released Wednesday afternoon, with the drug demonstrating "81 per cent interim efficacy in preventing COVID-19 in those without prior infection after the second dose", according to a statement by the company.
-
Bharat Biotech Gets Centre's Letter For 45 Lakh Doses Of Covaxin: Report
Bharat Biotech has secured a fresh Letter of Comfort from the Centre for another 45 lakh doses of its COVID-19 vaccine, Covaxin, sources said.
-
"Every Indian Proud That Vaccines Given Approval Made In India": PM Modi
India COVID-19 Vaccine: It would make every Indian proud that the two COVID-19 vaccines given go-ahead by the country's drug controller are "made in India", PM Modi today said within minutes of the approval being made public.
-
India A Step Closer To Covid Vaccine, Drug Regulator Approval Awaited: 10 Facts
India has moved a step closer to getting a coronavirus vaccine as two candidates - Hyderabad-based Bharat Biotech's Covaxin and the Serum Institute of India's Covishield - have been recommended by a government-appointed panel to the Drugs Controller General of India (DCGI) for emergency use in the last two days. The country has been preparing for t...
-
Coronavirus Highlights: Oxford COVID-19 Vaccine Covishield Approved For Use In India
India's drugs regulator on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
-
Coronavirus LIVE Updates: Bharat Biotech Seeks Emergency Use Approval For Covaxin
Coronavirus Updates: India recorded 32,981 new COVID-19 cases in the last 24 hours, taking the total number of active coronavirus cases in the country to 3,96,729, said the Union Ministry of Health and Family Welfare on Monday.
-
Vaccine Maker Clarifies As Haryana Minister, A Volunteer, Tests Covid+
Covaxin, India's first indigienous vaccine for the highly infectious coronavirus, has been designed to be effective if a person takes two doses, Hyderabad-based pharmaceutical firm Bharat Biotech clarified in a statement on Saturday, stressing that the "efficacy can be determined 14 days after the second dose".
